Skip to main content

Table 2 Uni- and multivariate logistic regression for disease recurrence within 12, 18, and 36 months

From: Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study

DFS Variable Grade
3 vs 2 vs 1
pT
4 vs 3 vs 2 vs 1
pN
2 vs 1
No harvested
≥ vs < 12
RDI-O
< 60 vs ≥ 60%
OR (95% CI); p
12 months Univariate analysis 2.82 (1.39–5.53); 0.003 3.03 (1.58–5.70); 0.001 1.78 (0.99–3.20); 0.051 0.59 (0.32–1.06); 0.078 2.04 (1.08–3.78); 0.024
Multivariate analysis 2.36 (1.09–4.93); 0.025 2.84 (1.40–5.65); 0.003 1.93 (1.03–3.63); 0.041 0.49 (0.25–0.92); 0.028 2.06 (1.03–4.01); 0.036
18 months Univariate analysis 2.45 (1.30–4.55); 0.005 1.93 (1.07–3.68); 0.027 2.23 (1.36–3.68); 0.002 0.61 (0.37–1.00); 0.051 2.05 (1.18–3.51); 0.010
Multivariate analysis 2.47 (1.25–4.80); 0.008 2.63 (1.55–4.54); < 0.001 0.51 (0.29–0.86); 0.013 1.91 (1.06–3.39); 0.028
36 months Univariate analysis 2.09 (1.15–3.80); 0.015 2.80 (1.62–4.88); < 0.001 2.17 (1.39–3.39); 0.001 0.62 (0.40–0.96); 0.034 1.50 (0.90–2.48); 0.117
Multivariate analysis 1.93 (1.02–3.65); 0.043 2.66 (1.49–4.79); 0.001 2.46 (1.53–4.01); < 0.001 0.46 (0.28–0.74); 0.001
  1. DFS Disease free survival, CI Confidence interval, OR Odds ratio, p Pathological, No Number, RDI-O Relative dose intensity of oxaliplatin